- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jeff White: Collaboration Is Key to Combatting Opioid Epidemic
Jeff White, PharmD, MS, staff vice president, Anthem, discusses what role Anthem has in addressing the opioid epidemic, as well as how important collaboration with other stakeholders is for addressing the epidemic.
Jeff White, PharmD, MS, staff vice president, Anthem, discusses what role Anthem has in addressing the opioid epidemic, as well as how important collaboration with other stakeholders is for addressing the epidemic.
TranscriptAs a payer, what role do you have in addressing the opioid epidemic?
Anthem has taken a national leadership role in addressing the opioid abuse epidemic. We set out a goal of reducing opioid use by 30% by 2019 from its peak in 2012. We’ve achieved that goal 2 years early. In fact, we’ve achieved over a 40% reduction in opioid use since the peak in 2012. So, Anthem has an important role in helping to address the opioid abuse epidemic.
How important is it to collaborate with other stakeholders in order to ensure success with these different initiatives?
This epidemic is so large and vast and complicated, it’s going to take effort from a number of different stakeholders to help address this epidemic. For example, the government, regulatory agencies, health plans such as Anthem, PBMs [pharmacy benefit managers], physicians, educating patients, are all necessary to help address the opioid abuse epidemic.
AI's Role in Oncology: Supporting, Not Replacing, Health Care Providers
January 9th 2025In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he discusses opportunities for advancing the smart use of artificial intelligence (AI) in cancer care.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurativa (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
